Dermbits

Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions
What characteristics of a localized inflammatory lesion make you more likely to consider Cordran Tape, and what have those cases taught you about the value of occlusion?
1:36
Jul 21, 2026Topical Therapies

What characteristics of a localized inflammatory lesion make you more likely to consider Cordran Tape, and what have those cases taught you about the value of occlusion?

-

In patients with chronic hand eczema and fissuring, what clinical or lifestyle factors make you consider Cordran Tape, and what have you observed in those cases?
1:31
Jul 21, 2026Topical Therapies

In patients with chronic hand eczema and fissuring, what clinical or lifestyle factors make you consider Cordran Tape, and what have you observed in those cases?

-

When treating patients whose disease is being perpetuated by scratching, rubbing, or picking, what advantages have you found Cordran Tape can offer beyond topical steroid delivery alone? 
0:57
Jul 21, 2026Topical Therapies

When treating patients whose disease is being perpetuated by scratching, rubbing, or picking, what advantages have you found Cordran Tape can offer beyond topical steroid delivery alone? 

-

How often do real-world lifestyle factors influence your treatment selection in localized inflammatory skin disease, and are there situations where Cordran Tape has helped address challenges that traditional topical regimens could not?
2:03
Jul 21, 2026Topical Therapies

How often do real-world lifestyle factors influence your treatment selection in localized inflammatory skin disease, and are there situations where Cordran Tape has helped address challenges that traditional topical regimens could not?

-

In inflammatory dermatoses, are there situations where changing the treatment strategy is more important than simply choosing a stronger medication?
1:33
Jul 21, 2026Topical Therapies

In inflammatory dermatoses, are there situations where changing the treatment strategy is more important than simply choosing a stronger medication?

-

How often do factors such as scratching, friction, repetitive trauma, or occupational exposure contribute to treatment resistance in dermatology?
1:02
Jul 21, 2026Topical Therapies

How often do factors such as scratching, friction, repetitive trauma, or occupational exposure contribute to treatment resistance in dermatology?

-

What types of psoriasis patients tend to fall into a treatment “gray zone,” and where has apremilast fit into your approach for those individuals?
1:06
Jul 6, 2026Psoriasis

What types of psoriasis patients tend to fall into a treatment “gray zone,” and where has apremilast fit into your approach for those individuals?

-

How do you set treatment goals with apremilast differently than you might with other systemic therapies?
0:52
Jul 6, 2026Psoriasis

How do you set treatment goals with apremilast differently than you might with other systemic therapies?

-

What have you learned about managing patients who improve on apremilast but do not achieve the level of response they initially hoped for?
1:16
Jul 6, 2026Psoriasis

What have you learned about managing patients who improve on apremilast but do not achieve the level of response they initially hoped for?

-

What factors most strongly influence whether patients feel successful on apremilast?
1:12
Jul 6, 2026Psoriasis

What factors most strongly influence whether patients feel successful on apremilast?

-

How do you approach psoriasis treatment decisions when objective measures and patient perception of disease severity do not align?
1:45
Jul 6, 2026Psoriasis

How do you approach psoriasis treatment decisions when objective measures and patient perception of disease severity do not align?

-

What challenges arise when treatment expectations are shaped by increasingly effective therapies for psoriasis?
0:41
Jul 6, 2026Psoriasis

What challenges arise when treatment expectations are shaped by increasingly effective therapies for psoriasis?

-

What do you do when coverage lags behind innovation?
1:30
Jul 1, 2026Vitiligo

What do you do when coverage lags behind innovation?

-

When does combination therapy complicate access—and how do you navigate it?
1:21
Jul 1, 2026Vitiligo

When does combination therapy complicate access—and how do you navigate it?

-

How do you manage access for patients with limited follow-up reliability?
1:42
Jul 1, 2026Vitiligo

How do you manage access for patients with limited follow-up reliability?

-

What documentation supports treatment escalation in stable but symptomatic disease?
1:07
Jul 1, 2026Vitiligo

What documentation supports treatment escalation in stable but symptomatic disease?

-

What documentation supports continued use of ruxolitinib over time?
1:25
Jul 1, 2026Vitiligo

What documentation supports continued use of ruxolitinib over time?

-

What clinical context supports ruxolitinib over other topical options?
1:13
Jul 1, 2026Vitiligo

What clinical context supports ruxolitinib over other topical options?

-

For patients with vitiligo, what do you focus on in the initial visit before patients even begin treatment with topical therapies?
1:40
Jun 10, 2026Vitiligo

For patients with vitiligo, what do you focus on in the initial visit before patients even begin treatment with topical therapies?

-

How do you counsel patients on the timeline of repigmentation with topical therapies for vitiligo?
0:53
Jun 10, 2026Vitiligo

How do you counsel patients on the timeline of repigmentation with topical therapies for vitiligo?

-

How do you explain differences in response between facial and nonfacial vitiligo when using topical therapies?
1:04
Jun 10, 2026Vitiligo

How do you explain differences in response between facial and nonfacial vitiligo when using topical therapies?

-

How do you counsel patients with vitiligo who are seeing partial improvement but not complete repigmentation?
1:14
Jun 10, 2026Vitiligo

How do you counsel patients with vitiligo who are seeing partial improvement but not complete repigmentation?

-

What are the most common adherence challenges you see with topical treatments in vitiligo?
1:18
Jun 10, 2026Vitiligo

What are the most common adherence challenges you see with topical treatments in vitiligo?

-

What should clinicians keep in mind when considering treatment for patients with long-standing vitiligo?
1:31
Jun 10, 2026Vitiligo

What should clinicians keep in mind when considering treatment for patients with long-standing vitiligo?

-